What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹86 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from Concord Drugs Limited's filed financials and exchange disclosures
Concord Drugs Limited is a Pharmaceuticals & Biotechnology company listed on BSE.
Yes. Over the trailing twelve months Concord Drugs Limited reported a net profit of ₹2 Cr on revenue of ₹86 Cr.
Not in the latest reported year — Concord Drugs Limited's dividend payout for FY26 was nil.
No. Debt stands at 0.28× equity, and it carries net debt of ₹13 Cr. That is lower than 31% of its 171 Pharmaceuticals peers.
On trailing P/E, Concord Drugs Limited ranks 123 of 169 in Pharmaceuticals — cheaper than 27% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session Concord Drugs Limited moves 1.99% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by Concord Drugs Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
